Related Experiment Video
Updated: Jul 2, 2026

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children
Michael G Aman1, Jill A Hollway, Sarah Leone
1The Ohio State University, USA.
Insights
Risperidone improved cognitive-motor skills, reduced disruptive behavior, and decreased tremor in children. However, it also led to increased heart rate and weight, indicating potential side effects.
Area of Science:
- Child and Adolescent Psychiatry
- Neuropharmacology
- Behavioral Science
Background:
- Risperidone is frequently used for disruptive behavior in children.
- Its effects on cognitive-motor function and specific movement disorders require further investigation.
Purpose of the Study:
- To evaluate the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children with disruptive behavior on maintenance therapy.
Main Methods:
- A crossover study design involving 16 children (aged 4-14 years) with disruptive behavior.
- Participants received risperidone and placebo for 2 weeks each, with random assignment to drug order.
- Measures included cognitive tests, movement assessments (tremor, activity, abnormal movements), and parent behavior ratings.
Main Results:
- Risperidone demonstrated superiority over placebo in response time and seat movement during a short-term memory task, and in reducing static tremor.
- No significant differences were found in the Abnormal Involuntary Movement scale between conditions.
- Risperidone improved specific behavioral aspects, including oversensitivity, conduct problems, and hyperactivity, as rated by parents.
Conclusions:
- Risperidone shows beneficial effects on cognitive-motor efficiency, activity levels, static tremor, and certain behavioral problems in children with disruptive behavior.
- Potential side effects such as increased heart rate and weight necessitate careful monitoring during risperidone treatment.
Abstract:
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2 weeks each. Dependent measures included tests of sustained attention, memory, visual matching, tremor, seat activity, abnormal movements, and parent behavior ratings. Results were compared by repeated measures ANOVA. Fourteen boys and 2 girls with disruptive behavior and IQ=84 all completed the protocol. Risperidone was superior to placebo on response time (p=0.01, eta(P)(2)=0.43) and seat movement (p<0.05, eta(P)(2)=0.29) on a short-term memory task, and on a measure of static tremor (p=0.05, eta(P)(2)=0.28). There was not a significant difference between treatment conditions on the Abnormal Involuntary Movement scale. Risperidone was superior to placebo on three subscales of the Nisonger Child Behavior Rating Form [Overly Sensitive (p<0.01, eta(P)(2)=0.44), Conduct Problem (p=0.02, eta(P)(2)=0.36), Hyperactivity (p=0.03, eta(P)(2)=0.32)] and on the Hyperactivity/Noncompliance subscale of the Aberrant Behavior Checklist (p=0.01, eta(P)(2)=0.41). Significant increases in heart rate (p=0.05, eta(P)(2)=0.27) and weight (p=0.02, eta(P)(2)=0.36) occurred in the risperidone condition. The findings suggest a beneficial effect of risperidone after several months of treatment on efficiency of responding, activity level, static tremor, and aspects of behavior.
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Psychosis: Goals of Pharmacotherapy
